Science

Apr 13, 2025, 09:33

Myeloma Paper of the Day, April 13th, suggested by Robert Orlowski

Robert Orlowski, Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:

“Myeloma Paper of the Day: Final analysis of ALCYONE shows median OS of 83.0 months with D-VMP vs. 53.6 with VMP; most common grade 3/4 TEAEs were neutropenia, thrombocytopenia and anemia; deaths due to TRAEs 1% in both; SPMs 8% with D-VMP vs. 6% for VMP.”

“Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trial”

Authors: Maria-Victoria Mateos, Jesus San-Miguel, Michele Cavo, Kenshi Suzuki, Andrzej Jakubowiak, Maria Krevvata, Kasey Bolyard, Robin Carson, Fredrik Borgsten, Meletios Dimopoulos et al.

More posts featuring Robert Orlowski.

ALCYONE Andrzej Jakubowiak cancer Fredrik Borgsten Jesús San-Miguel Kasey Bolyard Kenshi Suzuki Maria Krevvata Maria-Victoria Mateos Meletios Dimopoulos Michele Cavo multiple myeloma Myeloma Paper of the Day OncoDaily Oncology Robert Orlowski Robin Carson

Neuroendocrine Lung Tumors: Types, Symptoms, Diagnosis, Treatment and 2025 updates

Cancer Center Near Me: Dana-Farber Cancer Institute

FDA Approves Nivolumab and Ipilimumab for First-Line Treatment of Unresectable Hepatocellular Carcinoma Based on CheckMate-9DW Trial

John Cena Announces He Overcame Skin Cancer Twice, Advocates for Sun Safety

William N. Hait to Receive 2025 AACR-Margaret Foti Award for Leadership in Cancer Research